Get the Stockscreener App
95.83
5.66%
-5.75
Genedx Holdings Corp stock is traded at $95.83, with a volume of 1.13M.
It is down -5.66% in the last 24 hours and up +28.87% over the past month.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
See More
Previous Close:
$101.58
Open:
$102.68
24h Volume:
1.13M
Relative Volume:
1.28
Market Cap:
$2.69B
Revenue:
$267.23M
Net Income/Loss:
$-83.50M
P/E Ratio:
-30.81
EPS:
-3.11
Net Cash Flow:
$-59.99M
1W Performance:
+25.51%
1M Performance:
+28.87%
6M Performance:
+177.77%
1Y Performance:
+1,279%
1-Day Range:
$90.26
$103.56
1-Week Range:
$90.26
$115.60
52-Week Range:
$6.79
$115.60
Genedx Holdings Corp Stock (WGS) Company Profile
Name
Genedx Holdings Corp
Sector
Industry
Phone
617 780 8742
Address
333 LUDLOW STREET, STAMFORD
Compare WGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
95.83 | 2.69B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
532.55 | 203.70B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.23 | 151.18B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
135.37 | 38.62B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
452.77 | 37.07B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
191.04 | 33.64B | 15.41B | 1.37B | 2.11B | 7.50 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-10-24 | Initiated | Craig Hallum | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
Genedx Holdings Corp Stock (WGS) Latest News
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Learn to Evaluate (WGS) using the Charts - Stock Traders Daily
The Goldman Sachs Group Forecasts Strong Price Appreciation for GeneDx (NASDAQ:WGS) Stock - Defense World
GeneDx (NASDAQ:WGS) Hits New 52-Week High on Better-Than-Expected Earnings - Armenian Reporter
Allspring Global Investments Holdings LLC Has $7.18 Million Position in GeneDx Holdings Corp. (NASDAQ:WGS) - Defense World
GeneDx Holdings Corp. SEC 10-K Report - TradingView
A Closer Look at GeneDx Hldgs's Options Market Dynamics - Benzinga
GeneDx Holdings Corp.: A Comprehensive Analysis - HPBL
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Investors to Connect - Markets Insider
Reviewing GeneDx Holdings: Exome Testing And EPIC Aura Integration Make It A GARP 'Buy' - Seeking Alpha
GeneDx Holdings Corp. (NASDAQ:WGS) Q4 2024 Earnings Call Transcript - Insider Monkey
GeneDx price target raised to $135 from $118 at TD Cowen - TipRanks
3 Stocks On US Exchange Estimated To Be Undervalued By Up To 36.2% - Simply Wall St
GeneDx Holdings Corp (WGS) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
GeneDx (NASDAQ:WGS) Hits New 52-Week High After Better-Than-Expected Earnings - Defense World
GeneDx Reports Strong 2024 Growth and 2025 Outlook - TipRanks
GeneDx Highlights Strong Growth in Earnings Call - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp.WGS - PR Newswire
GeneDx Stock Was up 2,700% in 2024 — Can It Keep Rising? - Investing.com
GeneDx Holdings Corp: A Stock on the Rise - RagingBull
Craig Hallum Raises GeneDx Holdings' Price Target to $114 From $95, Keeps Buy Rating - Marketscreener.com
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
GeneDx targets $350M-$360M revenue for 2025 with 30% growth in exome and genome testing - MSN
Earnings call transcript: GeneDx Q4 2024 beats forecasts, stock surges - Investing.com
GeneDx Holdings earnings beat by $0.56, revenue topped estimates - Investing.com
GeneDx Holdings Corp. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
GeneDx Swings to Adjusted Net Income, Revenue Rises; 2025 Revenue Guidance Set - Marketscreener.com
GeneDx Holdings Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025 - BioSpace
Genedx Holdings Corp FY 2025 Revenue Guidance Of $350M To $360M -February 18, 2025 at 06:20 am EST - Marketscreener.com
GeneDx Holdings Corp. Provides Earnings Guidance for the Full Year of 2025 -February 18, 2025 at 06:00 am EST - Marketscreener.com
GeneDx Holdings Corp. (NASDAQ:WGS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? - Benzinga
GeneDx (WGS) Projected to Post Earnings on Tuesday - Defense World
GeneDx (WGS) Expected to Announce Earnings on Tuesday - MarketBeat
GeneDx (NASDAQ:WGS) Shares Up 8%Should You Buy? - MarketBeat
Legato Capital Management LLC Has $2.13 Million Stake in GeneDx Holdings Corp. (NASDAQ:WGS) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Reach Out - Markets Insider
GeneDx launches ultrarapid whole genome sequencing for critically ill infants - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating GeneDx Holdings Corp. (WGS) And Encourages Stockholders to Connect - Markets Insider
GeneDx speeds up genome sequencing for NICU care By Investing.com - Investing.com South Africa
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients - Business Wire
GeneDx (NASDAQ:WGS) Shares Down 6.7%Should You Sell? - MarketBeat
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against GeneDx Holdings Corp. (WGS) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
GeneDx (NASDAQ:WGS) Stock Price Down 6.7%What's Next? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages GeneDx Holdings Corp. (WGS) Investors to Inquire about Securities Investigation - Markets Insider
Closing Strong: GeneDx Holdings Corp (WGS) Ends at 59.54, Down -4.23 from Last Close - The Dwinnex
Genedx Holdings Corp Stock (WGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genedx Holdings Corp Stock (WGS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jan 29 '25 |
Option Exercise |
0.00 |
753 |
0 |
3,225 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jan 29 '25 |
Sale |
78.48 |
275 |
21,582 |
2,950 |
| Stueland Katherine | Chief Executive Officer |
Jan 29 '25 |
Option Exercise |
0.00 |
3,874 |
0 |
5,594 |
| Stueland Katherine | Chief Executive Officer |
Jan 29 '25 |
Sale |
78.48 |
1,657 |
130,046 |
3,937 |
0.06%
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):